Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 161–170 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 161
- Medicine slug
- azithromycin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 162
- Source count
- 160
- Agreement rate
- 1
- Recorded readings
68 hr
- Numeric value
- 68
- Unit
- hours
- Source records
- 160
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 160 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ab854bf-eb04-42c4-a403-096b60581bb4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d564d91e-3039-c120-e053-2995a90ae6db (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b08bd8fc-20da-4623-9211-ae669452b16d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f36ba37-a742-41c1-ad2d-b890a1d49c55 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45410338-6bff-476b-b8e1-6c6238205a99 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1755cf3-bf7f-be40-e053-2a95a90a8536 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc99fae-a72c-8893-e063-6394a90aa3ef (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47a8fd64-5a3d-490e-8ca8-5e6721c830cf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:405ab07f-7d1d-4552-ad3b-2a03be8e9949 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24c07398-84ad-48e2-9625-e9073c28fb73 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:943b9246-7733-44b1-875c-91d2ade78ac4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7ed6985-1d1d-48af-9df8-64b12821789e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acce3c1-f4be-4968-a71f-3ffd9fbaa4a4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ed68b5a-4093-49f1-871b-7b0da5f7be2d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8037c6f4-4881-4740-8229-2aee56141cd0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cefbce3f-3e6c-4659-abd7-3ec3e8227737 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:661ff7a6-6394-493d-a307-a1f607e5d117 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f144e92-c9eb-420a-9bb8-4265a9f20a98 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6caeda98-7020-413a-9461-04f476dad4ba (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b631aa1-2d46-40bc-a614-d698301ea4f9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:882f71b1-b153-4856-b4a7-1a29ae9cf247 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a52c0b-45db-422e-8c22-e867a11b4439 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d0a4eb-5076-65c6-e063-6394a90ac13a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0138503-ddc4-2e1c-e053-2995a90a0d2d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99ca0089-14a9-446d-8807-253ad5be3efa (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf098d5-dfd5-4a0d-81f7-6afa1a203a27 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6169e56c-10fb-448d-ab0f-14e54fcf2817 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3745a0b0-7855-69eb-e063-6294a90ab6a8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6fb42ed-7dac-4a7b-9964-d367dd47dd5c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6426d5f-5518-3c69-e053-2995a90af50f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc633b7d-5154-7e43-e053-2a95a90ad2a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b7e16b1-9a3c-4e3a-8411-841a708afe45 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21c67de0-3a4e-caab-e063-6394a90ae3cd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c44af6d-8a9a-cb4c-e053-2a95a90afdac (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81212ef-76b6-4bd7-8706-3d2b05ee34f9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df9b39b7-d42d-4c4b-b492-9fd228978dec (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43d23c7-1a2e-ce93-e053-2995a90a65a4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549cdd0a-da79-23b8-e054-00144ff8d46c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34e6364a-ac3d-434e-a90c-cb13ebcf7983 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e65b83-32d6-40bc-be5d-19fbec051bdf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c95c30-564f-4b67-ac6d-9179cdfaa5a8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba57ff26-cd02-4f57-ac92-b613d245a4ea (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4278e306-bc26-4282-93ce-f1405e0b5d4a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f97d2e7e-ccfd-4f04-85ba-549b37f6aa7b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2065c4ba-e3f5-41a2-b3d5-205dab646924 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e2163b-af61-4323-8b9c-2d44fc122fd9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f7c7421-411d-c04e-e063-6394a90a4aa0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4196e616-bdd8-9e88-e063-6394a90ac81d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac327054-21ab-401c-a27a-48259db18f89 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77c5e4c6-6d16-40fe-bf36-cb441348f39b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5d79719-b1dc-469f-a19c-f8ba615138f0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d78cd8e-0c63-46d6-b018-939fcbbe42a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c4861f2-825e-4e3b-9907-9658a849079e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c926669-62b2-4ad3-8289-173c5818a9c1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:397471e5-76e2-462c-af30-bcc54fe00266 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5b4092d-ab72-f5d1-e053-2995a90ac582 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ddecd25-dc32-a2af-e063-6294a90a526d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94e17ae5-0871-67a0-e053-2995a90ae0ae (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac549022-4d7f-4c9f-9244-1a2df9a27276 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c902990-b870-4725-b9fe-76b8be633e1c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af720986-48a9-48b5-bdd7-370f6a2f92e1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8d012c4-f411-4484-a618-7597599ea621 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b821631-0df2-0fb2-e054-00144ff8d46c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:826f9c07-8eb9-a128-e053-2991aa0ad654 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8389c336-25eb-a96f-e053-2a91aa0a0dd8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edecf20d-c681-418b-9c47-02fb32d2b3c0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90605f94-93e1-43d1-8be7-830e816ac84f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610a34ea-6aa7-4b94-a85a-ff16ca537d03 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9800bbe-e8bf-4689-a8a5-dc23b5d2ee56 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c84aea-7ba7-4aae-999c-db740a9e53df (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e4fbd52-43e4-4d87-a136-f4d680a8d0c1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8010dc-700f-45d3-94ca-ebe4a51acc1b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58308e8b-57bd-4e82-a2e8-24aac63194cd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f9e13f5-69ee-4220-90d9-31fa8660d880 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dca5a11-3c02-4a51-a35d-f91f37b8e00c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a2bdcb-3012-42fb-ac66-d1d879100940 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82454fb2-e524-ecb8-e053-2991aa0a6e7c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20ae108a-00c5-a984-e063-6394a90aaaae (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6497fb5e-82d8-4411-b994-7ee01333ffd7 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad099d5-5c57-4855-98a4-e03fb4629dbf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4c05e22-4a54-4948-abf8-8a479d465d30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb97a057-2537-41ae-b50c-a80605039c30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d24bacb-feff-4c6a-b8df-625e1435387a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7711e846-0bb3-486c-8511-f445e264cd98 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9990a1d-5238-403e-9221-72a9314d7b5e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:714f6f55-278a-4fcf-8d4e-2ad9b43623a3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e7184e1-3c3c-cd87-e053-2a95a90a6eb6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b88f5839-8e8b-4bf6-a577-5c8b7cffeec6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9270e676-3382-6483-e053-2a95a90a556e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a4d2b3-daea-4d96-891f-4b9823629456 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8e106cb-7245-45a5-9aad-bd624b1e011d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25bc2e78-9d0d-41c6-a55e-a267d4457967 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1f4b5-6c32-3075-e063-6294a90a0d4b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c9de2e9-c20c-4660-a272-a22019f9fb02 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333ffe63-aaeb-4dff-b595-1c11209189a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d4ac05-b564-440c-971d-b78590dd2c32 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1172805-0930-4fb9-8a2f-e0d6a0430630 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2754618-3df1-4b89-aa09-fdff4b71b7e4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25f2d819-ae38-4061-a897-bbcfce3739bf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33140df5-420d-469f-b6c8-121e952a5cb6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:258dd3c5-dce9-7483-e063-6294a90a4043 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e6e11fb-eb9e-28ec-e053-2a95a90aa1a3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:324330c5-20fe-4b22-adf2-14a6e91e71ef (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3209b147-11ce-4eeb-8427-5f8e6fb2c83d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4314da8a-40e5-4aba-a32b-57b4166ade30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf061799-cdef-40f8-b1ce-bc5eb609f8c3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d5129e4-8b94-4a4d-baa9-be0d6b32d714 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f52ce0-ad3f-7d80-e063-6294a90ad086 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b90572c-cc24-49f0-baaf-09022a2f9a00 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de5b0c2b-9a7d-46e9-8169-4100442efa9b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:003307c5-3f73-4a5d-a704-bfdea3c656e8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea128124-8712-4998-be46-47d43ef127d4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:510024c9-6658-e08f-e063-6294a90a0793 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76093152-e2d7-4fe1-8568-1f0fec1747c2 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cdb5ae-2aeb-c598-e053-2a95a90a8062 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b70c23-92a6-460f-8dbb-15a0e6b9d3a9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55051e03-b6dc-4bc6-87c1-e4fb84b61fa3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec619299-e0ef-44dd-acdb-8c53bbfc5b8a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99e5bd22-a721-4e2e-a46c-d61a53c25c3d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:859bb02c-a4bc-46fa-9fc9-def1219b5dfb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd25741-f014-3999-e063-6394a90acdd0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f0501bf-d1c4-46a5-b253-3b9e61015e82 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deea1a56-84ed-4ce4-9d11-03271510c0a1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a22beb6-57e8-480d-97b5-44d9dbfabf93 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a506cd-aae7-a622-e053-2a95a90ad352 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b69917c0-95d5-4b29-b0e3-07054a4fd79f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1752913-85ac-01fa-e053-2995a90a2bd8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e7c2f49-449c-4ba2-98ae-0ff0c040614c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and i.v. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da399401-1ee6-422a-be46-0bba6b264b2f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b635019e-7fd4-7f9e-e053-2a95a90a388c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0cfda1a-910f-4764-8658-263037df5ea8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60ec2020-148b-4a2a-96f2-dd09c590ecbb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1c96531-bbd2-4dc5-8eeb-3f0276cd0956 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b66736-3f1a-4d6d-bdc4-274f5adfb40c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:795c13cd-e9ca-481b-9fa9-2890bdf9dac8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01649d79-4677-4577-a3e4-e054f3f9fc3b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b81436e-d14a-4353-a22d-253f45e2e576 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4eec460d-5ba8-4614-8700-219a9b4fc385 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b77b347d-d357-4bdf-b985-49d9a1dd634c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44134421-cb0b-4e85-a3c8-d58bdb476fad (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and i.v. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb40f4cf-15ae-47ab-8e0a-979467fa0d9e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb2f83a2-507b-4cf3-81ea-d10c46c0f8ea (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39a808c4-72ac-48e4-bfb8-e5ae3429b225 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90ff7cfc-73c9-4d77-83df-c05cfbbbbecd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3761d39-9b79-4908-8b05-a1c91e599998 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:896cce83-23ac-f4ed-e053-2a95a90ad107 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c84a68b-3eaa-4dab-b5e5-e195c7652e67 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cec44fa-9597-3e58-e063-6394a90ae326 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f175496a-4ad3-ce0d-e053-2a95a90a6613 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc93e72-95ce-965b-e063-6394a90a8917 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38942011-f86b-4e42-a4ca-05a70d9dd3d9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2b0c06b-e93d-f5aa-e053-2995a90ac9aa (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16da30a2-d11c-7e8c-e063-6294a90a62e3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11446677-a3dc-40cb-897d-7a9851b8c89c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59c4b783-4ff7-4269-969b-58a10e12b12b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3962bc34-8236-4ac1-8ffd-2edbd430c3eb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5199689f-8881-7757-e063-6394a90ae2eb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db52b91e-79f7-4cc1-9564-f2eee8e31c45 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814abe38-da4a-48af-bf4b-2ce04a5aabd1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68hr.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:614cc2a4-3fc7-455d-9e8a-212c496f0fbf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Elimination Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
Projected row 162
- Medicine slug
- azithromycin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 162
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
31.1 L/kg
- Numeric value
- 31.1
- Unit
- L/kg
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e65b83-32d6-40bc-be5d-19fbec051bdf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac549022-4d7f-4c9f-9244-1a2df9a27276 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dca5a11-3c02-4a51-a35d-f91f37b8e00c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9990a1d-5238-403e-9221-72a9314d7b5e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b88f5839-8e8b-4bf6-a577-5c8b7cffeec6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2754618-3df1-4b89-aa09-fdff4b71b7e4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d5129e4-8b94-4a4d-baa9-be0d6b32d714 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b70c23-92a6-460f-8dbb-15a0e6b9d3a9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e7c2f49-449c-4ba2-98ae-0ff0c040614c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Following oral administration, azithromycin is widely distributed throughout the body with an apparent steady-state volume of distribution of 31.1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44134421-cb0b-4e85-a3c8-d58bdb476fad (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Following oral administration, azithromycin is widely distributed throughout the body with an apparent steady-state volume of distribution of 31.1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc93e72-95ce-965b-e063-6394a90a8917 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16da30a2-d11c-7e8c-e063-6294a90a62e3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues.
Projected row 163
- Medicine slug
- aztreonam
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
1.7 hours
- Numeric value
- 1.7
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a105eaf-ee77-4016-beeb-d425a5565db2 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6cf7e13-a04e-47e2-9cec-44a278ee6bec (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d5515e-54bc-4efc-9f49-8ee3e88c3e01 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f5ebb63-6ac5-4fb4-bcc1-d069c123eb18 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4500795-3b07-4a7d-b432-73cafbb3dbc6 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2) in subjects with normal renal function, independent of the dose and route of administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302fd27d-0a22-44ea-91fb-1b1ffcf17a1f (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
The serum half-life of aztreonam averaged 1.7 hours (1.5-2.0) in subjects with normal renal function, independent of the dose and route of administration.
Projected row 164
- Medicine slug
- aztreonam
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
56%
- Numeric value
- 56
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a105eaf-ee77-4016-beeb-d425a5565db2 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of AZACTAM every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6cf7e13-a04e-47e2-9cec-44a278ee6bec (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of aztreonam for injection every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d5515e-54bc-4efc-9f49-8ee3e88c3e01 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of AZACTAM every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f5ebb63-6ac5-4fb4-bcc1-d069c123eb18 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of aztreonam for injection every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4500795-3b07-4a7d-b432-73cafbb3dbc6 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of aztreonam for injection every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302fd27d-0a22-44ea-91fb-1b1ffcf17a1f (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
Intravenous or intramuscular administration of a single 500 mg or 1 g dose of aztreonam for injection every 8 hours for 7 days to healthy subjects produced no apparent accumulation of aztreonam or modification of its disposition characteristics; serum protein binding averaged 56% and was independent of dose.
Projected row 165
- Medicine slug
- aztreonam
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
12.6 liters
- Numeric value
- 12.6
- Unit
- L
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a105eaf-ee77-4016-beeb-d425a5565db2 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6cf7e13-a04e-47e2-9cec-44a278ee6bec (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d5515e-54bc-4efc-9f49-8ee3e88c3e01 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f5ebb63-6ac5-4fb4-bcc1-d069c123eb18 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4500795-3b07-4a7d-b432-73cafbb3dbc6 (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302fd27d-0a22-44ea-91fb-1b1ffcf17a1f (opens source in a new tab)
Aztreonam label
Version not recorded · Effective date not recorded
In healthy subjects, based on a 70 kg person, the serum clearance was 91 mL/min and renal clearance was 56 mL/min; the apparent mean volume of distribution at steady-state averaged 12.6 liters, approximately equivalent to extracellular fluid volume.
Projected row 166
- Medicine slug
- baclofen
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 171
- Source count
- 23
- Agreement rate
- 0.434783
- Recorded readings
1.51 hours
- Numeric value
- 1.51
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077aaf3b-1ca3-4599-a51a-6bbe39810ca8 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus: After a bolus lumbar injection of 50 or 100 mcg baclofen injection (intrathecal) in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68c9ade0-d783-43e9-8a3f-a16ec1501ec1 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus After a bolus lumbar injection of 50 mcg or 100 mcg intrathecal baclofen in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f3bdcc0-ffc8-4911-8c35-958c8103a2c5 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus: After a bolus lumbar injection of 50 or 100 mcg LIORESAL INTRATHECAL in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d63af5f0-c275-480b-89b5-6cf1ad55ab63 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus After a bolus lumbar injection of 50 mcg or 100 mcg intrathecal baclofen in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea32c39c-0ee3-4b5e-8da7-4c31db334bd8 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus: After a bolus lumbar injection of 50 or 100 mcg Baclofen Injection in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4bfba33-9f4d-4c43-ae6c-bcf67ef8fe51 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus After a bolus lumbar injection of 50 mcg or 100 mcg intrathecal baclofen in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00d3e846-dd92-448d-9ab8-6a07be823cc1 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus After a bolus lumbar injection of 50 mcg or 100 mcg intrathecal baclofen in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e05080ef-53d9-4060-aaa4-86a6935467de (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus: After a bolus lumbar injection of 50 or 100 mcg Baclofen Injection in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa6148c-693c-45f1-89be-0e77d39f313e (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus After a bolus lumbar injection of 50 mcg or 100 mcg intrathecal baclofen in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ba5575-a856-414a-89f8-17f3a01de55b (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Intrathecal Bolus: After a bolus lumbar injection of 50 or 100 mcg baclofen injection (intrathecal) in seven patients, the average CSF elimination half-life was 1.51 hours over the first four hours and the average CSF clearance was approximately 30 mL/hour.
5.7 hours
- Numeric value
- 5.7
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ec79c6-da65-4fb6-b6bd-45df0d2a52c7 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:890df151-f4eb-4244-97c4-f1f10912e753 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a43830f-a28b-ca15-e063-6294a90a6b1a (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8ddcec5-debe-42b4-a803-e65917cc6a54 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2422746c-afec-ad30-e063-6394a90a0403 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75ab298b-b2a7-458f-accc-5bfc89b89a16 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81a539b3-e547-4a62-ad1b-2eedb30be927 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b3e7be-832b-313d-e063-6394a90a5ab4 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
5.6 hours
- Numeric value
- 5.6
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fad5ffc-afae-4c92-a672-ee636df45bc5 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c73ed3af-8e8a-4a18-90fc-a0f2dcc641d0 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of FLEQSUVY oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4585aafe-0af8-4786-a419-6a7e76671ca2 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
5.5 hours
- Numeric value
- 5.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8992a56-9010-4c4b-84d5-ddcc3e2c3317 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen oral granule formulation were achieved in about one hour and the apparent elimination half-life is about 5.5 hours.
Projected row 167
- Medicine slug
- baclofen
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 171
- Source count
- 12
- Agreement rate
- 0.666667
- Recorded readings
0.75 hours
- Numeric value
- 0.75
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ec79c6-da65-4fb6-b6bd-45df0d2a52c7 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:890df151-f4eb-4244-97c4-f1f10912e753 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a43830f-a28b-ca15-e063-6294a90a6b1a (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8ddcec5-debe-42b4-a803-e65917cc6a54 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2422746c-afec-ad30-e063-6394a90a0403 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75ab298b-b2a7-458f-accc-5bfc89b89a16 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81a539b3-e547-4a62-ad1b-2eedb30be927 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b3e7be-832b-313d-e063-6394a90a5ab4 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
The peak plasma concentrations were achieved in about 0.75 hours from oral solution and the apparent elimination half-life is about 5.7 hours.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fad5ffc-afae-4c92-a672-ee636df45bc5 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c73ed3af-8e8a-4a18-90fc-a0f2dcc641d0 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of FLEQSUVY oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4585aafe-0af8-4786-a419-6a7e76671ca2 (opens source in a new tab)
Baclofen label
Version not recorded · Effective date not recorded
Absorption The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.
Projected row 168
- Medicine slug
- benazepril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 56
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdf5144-752d-456f-b46d-19cbba0bc3d7 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of benazeprilat in pediatric patients was around 5 hours, one-third that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be41d21c-4747-47bb-b4b7-bbfabcd7a9b1 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of benazeprilat in pediatric patients was around 5 hours, one-third that observed in adults.
Projected row 169
- Medicine slug
- benazepril
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 56
- Source count
- 56
- Agreement rate
- 1
- Recorded readings
96.7%
- Numeric value
- 96.7
- Unit
- %
- Source records
- 56
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 56 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb93e793-fe4f-452c-e053-2995a90a7333 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9987a842-07a5-635e-e053-2995a90afa32 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ddcfbc-c9d8-45b1-9c11-0d1eff8c1e9e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 mcmol/L to 23.6 mcmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd616b9-0c75-48be-862d-5ac18364fd9d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01a3c9f6-41aa-47a7-8c56-5462c6b54416 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd1a7c8f-cc61-4ee4-a259-0b3329cced3e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b02c240-4393-48ed-a385-561ced7b7abf (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9535ec77-2d50-4817-e053-2995a90a007e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:471cd30a-401a-c8f9-e063-6294a90a4787 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f9dc46-a947-7ae3-e053-6394a90a1192 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:355811f0-2885-0d49-e054-00144ff8d46c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3631d1dc-45e1-0588-e054-00144ff88e88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:708110e5-fa45-44e0-9011-261f4490ea45 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09e383a8-e912-4cf7-8fb3-05545af80dd0 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc4cd253-13ee-9424-e053-6394a90a35a8 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c24bb4c-42d2-483a-b33f-95182b32b93d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55c99902-3d4d-05e9-e054-00144ff8d46c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e4e43a-7abc-e2a5-e053-2995a90ab5f4 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:700c828c-86c6-1857-e053-2a91aa0ae314 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d5362b-f5da-4838-ae91-22f40fcca245 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5090372-41bf-4677-b198-97fd55a0cb87 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800f2a14-98b9-3499-e053-2991aa0a197d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53fea330-cc4a-3b7e-e054-00144ff88e88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08bc0034-3b33-47d8-aec2-b36535ac85a2 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df13d8d8-0d70-4d6f-9dd1-5da38fbe2562 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 µmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a7b373a-9b74-4b9d-93fb-081614222e30 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a3d0f7-d2df-4230-ad9e-b32f7312d337 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aac6a2f-85fb-4c7a-b424-9c253186dffe (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32d01db-655b-f3d0-e053-2a95a90a04f6 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de2ea54-877d-46e9-b4c2-bf1ab9d0f19c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58977ec4-36ea-4d81-a8f0-7298425cbc84 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:449e89a3-7bef-44eb-8d73-c77ece611cce (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313225d7-f947-40b3-96d7-289aad300a4a (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9593989f-3129-48ad-9b30-f0b52fb3e91e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99755c59-18b9-ab7b-e053-2a95a90a4155 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0653322d-70c6-45f7-a9d1-41efee1d7387 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:910dac3a-728c-4f94-a514-e2b8f4680d39 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 µmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f004d7e2-fc45-8a37-e548-eeaaa327f9b5 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:032ea0f7-3304-4778-b3a6-6125ea7537ab (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdf5144-752d-456f-b46d-19cbba0bc3d7 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a26516-3d84-4d7a-a770-523926507887 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fade97e1-8400-4214-b750-e7656cae7a0f (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff732cfa-9ded-4226-b464-19c90a6865ae (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 µmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a216253b-27cb-42ef-b5a8-67fb05aafb88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5a8b50-dd2f-4329-9e28-93608e8fe8da (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0d3122a-5332-4af6-98d8-520ed70ace62 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 - 23.6 µmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb91223e-ffa5-4a3a-b191-fe121250c20c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9016634a-1bdd-700d-e053-2995a90a8f27 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be41d21c-4747-47bb-b4b7-bbfabcd7a9b1 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7274fdaf-1247-2b2f-e053-2991aa0ad3f6 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f46e2c9-9b3b-48d0-a307-9069e3879959 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99d3d0d-cee8-b260-e053-6294a90ac3cb (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 mcmol/L to 23.6 mcmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f265e6dd-f47e-4511-9468-282184bcd1b1 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc12ab4-2282-412f-8aa1-46ec5fbbab8f (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 µmol/L).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67c64de1-5579-46e4-82ee-c9bbee708e02 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
The serum protein binding of benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24 to 23.6 μmol/L).
Projected row 170
- Medicine slug
- benazepril
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 56
- Source count
- 56
- Agreement rate
- 0.589286
- Recorded readings
0.5 to 1.0 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb93e793-fe4f-452c-e053-2995a90a7333 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9987a842-07a5-635e-e053-2995a90afa32 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd616b9-0c75-48be-862d-5ac18364fd9d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01a3c9f6-41aa-47a7-8c56-5462c6b54416 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hour, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9535ec77-2d50-4817-e053-2995a90a007e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:471cd30a-401a-c8f9-e063-6294a90a4787 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:355811f0-2885-0d49-e054-00144ff8d46c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3631d1dc-45e1-0588-e054-00144ff88e88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:708110e5-fa45-44e0-9011-261f4490ea45 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c24bb4c-42d2-483a-b33f-95182b32b93d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55c99902-3d4d-05e9-e054-00144ff8d46c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e4e43a-7abc-e2a5-e053-2995a90ab5f4 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:700c828c-86c6-1857-e053-2a91aa0ae314 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53fea330-cc4a-3b7e-e054-00144ff88e88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08bc0034-3b33-47d8-aec2-b36535ac85a2 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hour, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df13d8d8-0d70-4d6f-9dd1-5da38fbe2562 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a7b373a-9b74-4b9d-93fb-081614222e30 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aac6a2f-85fb-4c7a-b424-9c253186dffe (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313225d7-f947-40b3-96d7-289aad300a4a (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99755c59-18b9-ab7b-e053-2a95a90a4155 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0653322d-70c6-45f7-a9d1-41efee1d7387 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hour, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:910dac3a-728c-4f94-a514-e2b8f4680d39 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:032ea0f7-3304-4778-b3a6-6125ea7537ab (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdf5144-752d-456f-b46d-19cbba0bc3d7 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril are reached within 0.5-1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff732cfa-9ded-4226-b464-19c90a6865ae (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5a8b50-dd2f-4329-9e28-93608e8fe8da (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0d3122a-5332-4af6-98d8-520ed70ace62 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hours and 1 to 2 hour, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of Lotensin, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb91223e-ffa5-4a3a-b191-fe121250c20c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be41d21c-4747-47bb-b4b7-bbfabcd7a9b1 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril are reached within 0.5-1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7274fdaf-1247-2b2f-e053-2991aa0ad3f6 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5-1.0 hours and 1-2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f46e2c9-9b3b-48d0-a307-9069e3879959 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc12ab4-2282-412f-8aa1-46ec5fbbab8f (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1.0 hour and 1 to 2 hours, respectively.
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ddcfbc-c9d8-45b1-9c11-0d1eff8c1e9e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd1a7c8f-cc61-4ee4-a259-0b3329cced3e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b02c240-4393-48ed-a385-561ced7b7abf (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f9dc46-a947-7ae3-e053-6394a90a1192 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09e383a8-e912-4cf7-8fb3-05545af80dd0 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc4cd253-13ee-9424-e053-6394a90a35a8 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d5362b-f5da-4838-ae91-22f40fcca245 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5090372-41bf-4677-b198-97fd55a0cb87 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800f2a14-98b9-3499-e053-2991aa0a197d (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a3d0f7-d2df-4230-ad9e-b32f7312d337 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32d01db-655b-f3d0-e053-2a95a90a04f6 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de2ea54-877d-46e9-b4c2-bf1ab9d0f19c (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58977ec4-36ea-4d81-a8f0-7298425cbc84 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:449e89a3-7bef-44eb-8d73-c77ece611cce (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9593989f-3129-48ad-9b30-f0b52fb3e91e (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f004d7e2-fc45-8a37-e548-eeaaa327f9b5 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a26516-3d84-4d7a-a770-523926507887 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fade97e1-8400-4214-b750-e7656cae7a0f (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a216253b-27cb-42ef-b5a8-67fb05aafb88 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9016634a-1bdd-700d-e053-2995a90a8f27 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99d3d0d-cee8-b260-e053-6294a90ac3cb (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril hydrochloride, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f265e6dd-f47e-4511-9468-282184bcd1b1 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril HCl, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hour and 1 to 2 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67c64de1-5579-46e4-82ee-c9bbee708e02 (opens source in a new tab)
Benazepril label
Version not recorded · Effective date not recorded
Following oral administration of benazepril, peak plasma concentrations of benazepril, and its active metabolite benazeprilat are reached within 0.5 to 1 hours and 1 to 2 hours, respectively.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=160Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.